Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 2/3 3Phase EARLY_PHASE1 2Phase 3 2Phase 1/2 2Phase 1 2Phase NA 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 1

Conditions

Stomach Neoplasms 1Neoplasms 1Melanoma 1Locally Advanced Rectal Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Radiotherapy 10Nivolumab 10Bevacizumab 10atezolizumab 8Radiation 8Platinum 8Pemetrexed 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Surgical Procedures, Operative 5Ipilimumab 5Immunoglobulin G 5Disulfides 5Cytarabine 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Immunotherapy × 90 days × Clear all
NCT07596290 2026-05-22

RADICAL

Beijing Friendship Hospital

Phase 2/3 Not yet recruiting
342 enrolled
Gastrointestinal

Locally Advanced Rectal Adenocarcinoma

NCT07000253 2026-05-07

OMEC-5

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2/3 Recruiting
290 enrolled
Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡